Sitemap > News > Technology
- Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B® in Systemic Lupus Erythematosus
- Progenics and Wyeth Announce FDA Has Accepted for Filing the New Drug Application for Subcutaneous Methylnaltrexone
- Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
- Celsion Completes Enrollment In Phase I Liver Cancer Study
- Data Show Improved Response Rate when Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
- Epeius Biotechnologies Gains Fda Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
- Xeloda® Plus Avastin® Combination Delays Disease Progression in Women with Advanced Breast Cancer
- CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
- Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
- CytImmune Presents Positive CYT-6091 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine Clinical Trial
- Introgen Reports Updated Phase 2 ADVEXIN(R) Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
- Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
- Oxford BioMedica and Sanofi-Aventis Report Encouraging New Trovax® Phase II Trial Results in Renal Cancer
- Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
- Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
- Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
- RESULTS OF VEGF TRAP (AFLIBERCEPT) HIGHLIGHTED AT ASCO 2007 ANNUAL MEETING
- OXFORD BIOMEDICA AND SANOFI-AVENTIS REPORT NEW TROVAX® PHASE II TRIAL RESULTS IN RENAL CANCER
- Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
- Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
- ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
- Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer.
- ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
- Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
- Antigenics’ QS-21 Stimulon Adjuvant Enters Phase 3 Clinical Trial of GlaxoSmithKline’s Novel Cancer Immunotherapeutic in Non-Small Cell Lung Cancer
- Biovest to File for Accelerated Conditional Approval of BiovaxID
- Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
- Genta Announces Results of Phase 1 Study using Genasense Administered by Intermittent Subcutaneous Injection
- Encouraging clinical activity of GSK’s novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
- Human Genome Sciences Announces Positive Final Results of Phase 2b Trial of Albuferon
- IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
- IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS WITH hPAM4 FOR PANCREATIC CANCER THERAPY
- Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
- ROXRO PHARMA’s novel intranasal pain reliever effective, well tolerated in phase 3 study
- XTL PROVIDES UPDATE ON PHASE I CLINICAL TRIAL OF XTL-2125
- YM BIOSCIENCES CLEARED TO INITIATE CLINICAL TRIAL OF NIMOTUZUMAB IN COLORECTAL CANCER
- Aspreva Announces Fast-Track Designation Granted by the FDA for CellCept in Lupus Nephritis
- Regeneron Submits Biologics License Application To U.S. FDA For IL-1 TRAP (RILONACEPT) For Treatment Of CAPS
- Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
- Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
- Abbott's HUMIRA (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
- Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
- FDA Accepts and Grants Priority Review of Erbitux (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001
- CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine
- Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted
- Human Genome Sciences Reports that a Phase 2 Study of Lymphostat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
- LCT successfully transplants first diabetes patient
- GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
- Novartis gains European approval for its innovative flu vaccine Optaflu
- Actemra: Roche´s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION study
- FDA Converts TELCYTA Full Clinical Hold to Partial Hold
- ACTEMRA™ (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to A Current Standard of Care
- Novo Nordisk and Neose announce initiation of phase 1 clinical trial of long-acting factor VIIa
- REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
- Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia® (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
- GENMAB ANNOUNCES DEVELOPMENT PLANS FOR OFATUMUMAB
- Phase I for Influenza vaccine adjuvanted with Intercell’s IC31 started
- Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
- Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL
- MorphoSys Announces Clinical Milestone in Partnered Therapeutic Antibody Program - Third HuCAL-based Antibody to Begin Clinical Trials
- Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials to Determine If Women With BRCA1 & BRCA2 Mutations May Receive Greater Benefit From New Treatment
- ALEXION’S SOLIRIS GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
- First Ad35-Based HIV-1 Vaccine Enters Phase I Clinical Trial at NIH
- Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar
- Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
- Genzyme Receives FDA Approval for New Labeling for Carticel
- Generex Biotechnology to Initiate Phase III Clinical Trial of Generex Oral-lyn in 2007 Third Quarter
- Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
- Vasogen Reports on Outcome of FDA Meeting
- YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF
- SciClone Initiates Phase 2 Clinical Trial Using SCV-07 to Treat Hepatitis C Patients
- Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
- Oncolytics Biotech Inc. Commences Patient Enrolment in U.S. Phase II Sarcoma Clinical Trial
- DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
- Alseres Pharmaceuticals Announces FDA Clearance to Increase Dose Level in Cethrin(R) Phase I/IIa Clinical Trial for Acute Spinal Cord Injury at U.S. Sites
- Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET(R) at International Myeloma Workshop
- Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
- Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
- Ablynx announces interim results of first Nanobody® Phase I study of ALX-0081 (anti-vWF)
- VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- Positive Trial Results - Combination Contraceptive Sprays
- BEMA Fentanyl NDA Submission Remains on Target for Third Quarter Following Meeting With FDA
- Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
- EMEA approves Kamada’s plans for phase II / III clinical trials of the aerosolized form of AAT for the treatment of Congenital Emphysema
- Genzyme Announces Results of Clinical Trial of Hylastan
- Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US
- Actemra: latest phase III study shows significant improvement in symptoms of patients with rheumatoid arthritis
- EMEA approves Kamada’s plan for phase II clinical trials of the aerosolized form of AAT for the treatment of Cystic Fibrosis
- EMEA approves Kamada’s plan for phase II clinical trials of the aerosolized form of AAT for the treatment of Cystic Fibrosis
- TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
- Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV
- California Biotechnology Company Takes Aim At Pancreatic Cancer With An Advanced Phase I/Ii Clinical Trial Using Rexin-G, A Targeted Injectable Gene Delivery System
- Vical Reaches Initial Enrollment Milestone in Phase 2 Trial of DNA Vaccine Against CMV
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- GERON INITIATES CLINICAL TRIAL OF TELOMERASE CANCER VACCINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
- Prolarix dose selected for phase 2 liver cancer study
- Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
- Phase II Study of IMC-A12 for Advanced Colorectal Cancer Has Commenced Patient Enrollment
- TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
- Protalix BioTherapeutics, Inc. Receives Special Protocol Assessment Approval from FDA for its Phase III Clinical Study of prGCD
- First child vaccinated with Intercell JE Vaccine in India - Pediatric Phase II trial started
- Acambis' universal influenza vaccine enters Phase 1 trial
- XOMA Initiates Phase I U.S. Trial in Type 2 Diabetes for XOMA 052, Monoclonal Antibody With Therapeutic Potential in Multiple Inflammatory Diseases
- FDA Approves First Gene- Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes
- FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
- GeoVax Annouces Start of 2 New HIV/AIDS Vaccine Human Trials
- Light Sciences Oncology Initiates Phase III Trial of Its Light Infusion Therapy (Litx) in Patients with Metastatic Colorectal Cancer
- Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
- EMEA Indicates that Genasense Approval in Melanoma Will Require Confirmatory Clinical Trial
- Medarex announce that its partner MedImmune has initiated a Phase Ib multi-dose clinical trial of MEDI-545 for the potential treatment of lupus
- Tercica Completes Enrollment of Clinical Trial MS301 Evaluating Treatment with Increlex in Children with Primary IGFD
- Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer
- Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites
- EpiCept Announces Phase III Study of EpiCept NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- Allergy Therapeutics says ragweed hay fever vaccine launch delayed by a year
- AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
- Nventa Announces Publication Of Final Results Of A Phase 2 Study Of HspE7 In Cervical Dysplasia
- Protalex Announces Preliminary Results in Phase I Clinical Trial
- Actemra monotherapy demonstrates significant clinical benefit in patients with rheumatoid arthritis
- OctoPlus announces promising results for Locteron Phase IIa clinical study
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- Targeted Genetics Provides Update on Inflammatory Arthritis Phase I/II Trial
- Targeted Genetics Provides Update on Inflammatory Arthritis Phase I/II Trial
- FDA Statement on Gene Therapy Clinical Trial
- Javelin Pharmaceuticals Begins Second Phase 3 Study of Dyloject
- AlphaVax Announces Interim Results from Phase 1 Influenza Vaccine Clinical Trial
- AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
- ImmunoGen, Inc. Earns Milestone with Start of Trastuzumab-DM1 Phase II Testing
- Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
- Iomai Vaccine Confers Statistically Significant Protection Against Travelers' Diarrhea in Phase 2 Study
- Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
- OncoGenex and Isis Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans
- YM BIOSCIENCES INITIATES PATIENT ENROLMENT IN PHASE II COLORECTAL CANCER TRIAL WITH EGFR ANTIBODY
- Joint FDA Advisory Committee Recommends Approval of TYSABRI® for the Treatment of Moderate-to-Severe Crohn’s Disease
- Antigenics Provides Update on Filing for Approval of Oncophage in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Enzon Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for Advanced Solid Tumors and Lymphoma
- Lev Pharmaceuticals Submits Biologics License Application for Cinryze
- MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
- Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus
- Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
- Unigene Initiates Oral Calcitonin Clinical Study in Humans
- Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
- Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD)
- Hana Biosciences Initiates Marqibo) Phase 2 Clinical Trial in Relapsed Acute Lymphoblastic Leukemia (All)
- Antisoma starts phase II trial of AS1411 in acute myeloid leukaemia
- Positive Phase 1b transdermal insulin clinical trial results
- Stem Cell Therapeutics Opens Second Clinical Trial Site for Its Lead Stroke Program
- GammaCan Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma
- ORENCIA® (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
- Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
- BioCancell reports completion of first part of clinical trial
- Tercica Receives Marketing Approval for Increlex in the European Union
- Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine
- Phase II Study of IMC-11F8 for Advanced Colorectal Cancer Has Commenced Patient Enrollment in Europe
- Roche Files IND for Second Genmab Antibody
- Pervasis Therapeutics Successfully Completes Enrollment for Vascugel Phase II Clinical Trials
- Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus
- Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
- Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis
- Kiadis Pharma Completes Patient Enrollment of Rhitol phase I/II Clinical Trial
- Targeted Genetics Reports Interim Phase II Data From HIV/AIDS Vaccine Clinical Trial
- YM BIOSCIENCES’, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
- ViaCell Expands Study Sites in ViaCyte Pivotal Trial
- Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
- Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
- Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
- MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
- DIAMYD UPDATES GENE THERAPY PROGRAM AND OUTLINES PLANS FOR PHASE I CLINICAL TRIAL FOR TREATMENT OF CANCER PAIN
- Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
- IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
- Ambrilia completes patient recruitment for the phase 3 pivotal clinical trial of its prolonged release formulation of Octreotide
- OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Thrombin Stand Alone, EVITHROM* Thrombin, Topical (Human), with General Hemostasis in Surgery Indication
- Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon® Trial Ahead of Schedule
- Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine
- Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
- Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment
- Pharming Presents Positive Results From European Phase III Trial Of Rhucin
- lmmutep Announces That ImmuFacf IMP321 Has Entered a Phase I Therapeutic Vaccine Trial in Melanoma
- YM BIOSCIENCES USA CLEARED BY US FDA TO INITIATE PHASE II CLINICAL TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER
- Merck Applies to Extend Use of Erbitux® for 1st-Line Colorectal Cancer
- GTC Obtains FDA Fast Track Designation for ATryn® and Permission to Submit a Rolling BLA
- Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
- Shire Undertakes Voluntary Market Withdrawal of a Limited Portion of Daytrana Product
- Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients
- YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
- AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
- Salix Pharmaceuticals Announces Statistically Significant Top–Line Results of a Unique Granulated Mesalamine Product Registration Study in Ulcerative Colitis
- LifeCycle Pharma Initiates Head-to-Head Clinical Trial of LCP-Tacro versus Advagraf
- Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
- Illumina Introduces the Infinium(R) HumanLinkage-12 Genotyping BeadChip
- Introgen\'s p53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
- ThromboGenics and BioInvent announce successful completion of phase I trial with TB-402
- Aranesp Study Showing No Negative Impact on Survival in SCLC
- ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
- Affymetrix Adds Mouse and Rat Arrays to Gene 1.0 ST System
- ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol)
- Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
- Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Xeloda® XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
- ATL1102 MS Phase IIa Trial Update
- LCT Receives Approval for DiabeCell® Clinical Trial in NZ
- Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
- Phosphagenics to commence a Phase 2 TPM/Insulin clinical trial
- Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- Genmab Discloses Target and Development Plans for HuMax-Inflam
- DAHANCA Initiates Head and Neck Cancer Study with Genmab’s HuMax-EGFr
- XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
- Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
- Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
- Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
- Vasogen Plans Confirmatory Study of Celacade™ in Chronic Heart Failure to Support U.S. Regulatory Approval
- Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study
- Sanofi pasteur\'s investigational H5N1 influenza vaccine achieves high immune response at low dosage
- View Summary Dynavax\'s HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
- Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
- TEVA PROVIDES UPDATE ON EDRATIDE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
- Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C™)
- Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
- ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
- FDA Approves Expanded Labeling for Campath to Include First-line Treatment for Leading Form of Adult Leukemia
- Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
- Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer\'s disease
- Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
- Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck\'s Investigational HIV Vaccine Candidate
- Phase 3 Pivotal Trial of TOCOSOL® Paclitaxel Does Not Meet Primary Endpoint
- Phase 1 transdermal oxycodone clinical trial approved
- Abbott Initiates Clinical Study to Evaluate Use of RX Herculink Elite Renal Stent System for the Treatment of Renal Artery Stenosis
- Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer - one of the most aggressive and fastest growing forms of the disease
- VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
- Pivotal Ustekinumab (CNTO 1275) Phase 3 Data To Debut At World Congress Of Dermatology Meeting
- DIAMYD® DIABETES VACCINE EFFECTIVE FOR AT LEAST 21 MONTHS
- Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
- Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
- GENMAB AMENDS OFATUMUMAB PIVOTAL STUDY IN NHL TO SINGLE ARM STUDY
- Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial
- Abbott\'s ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
- Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
- Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer
- ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
- PROMISING PHASE 3 TRIAL RESULTS SHOW NOVEL BIOLOGIC THERAPY USTEKINUMAB (CNTO 1275) SIGNIFICANTLY IMPROVED PSORIASIS USTEKINUMAB (CNTO 1275) SIGNIFICANTLY IMPROVED PSORIASIS
- Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
- Genzyme Receives Approval to Market Elaprase® in Japan
- MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
- Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in Europe
- GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
- Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer Study Released
- Biothera initiates Phase Ib/IIa clinical trial in cancer patients
- First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage Cancer Vaccine in Glioma
- GENMAB AMENDS HUMAX-CD4 PIVOTAL STUDY IN CTCL
- Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
- Pharming Receives Orphan Drug Designation For Recombinant Fibrinogen From FDA
- Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
- BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI® for Crohn\'s Disease
- Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- CLINICAL STUDIES SHOW REMICADE® REDUCES INCIDENCE OF BOWEL SURGERIES IN ULCERATIVE COLITIS PATIENTS
- Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
- Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID
- Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout.
- Authorization for AGENDA Phase 3 Trial of Genasense® in Advanced Melanoma Granted by French Regulatory Agency
- Interim Safety Data Favorable for Vical\'s Phase 2 Trial of DNA Vaccine Against CMV
- Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
- Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal™ as a First Line Treatment for Acute Graft vs. Host Disease
- U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
- OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
- Abraxis BioScience Receives a Positive Opinion in Europe from the CHMP for the Approval of ABRAXANE for the Treatment of Metastatic Breast Cancer
- Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
- Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus®
- Hospira\'s Biosimilar Epoetin Retacrit™ Receives Positive Opinion Recommending EU Approval
- Nventa Updates Progress of Cervical Dysplasia Trial with New HSPE7
- Interim Safety Data Favorable for Vical\'s Phase 2 Trial of DNA Vaccine Against CMV
- FDA Expands Age Range for Use of Bacterial Meningitis Vaccine
- Illumina Launches MicroRNA Assay for Gene Expression Profiling
- ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
- Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
- Kamada to start phase II clinical trials of the aerosolized form of AAT for the treatment of Cystic Fibrosis
- Further positive preliminary data on Diabecell trial
- Orphan Australia receives registration approval for the new dose form DepoDur™ modified release injection of morphine sulfate
- Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- MabCampath Receives Positive Opinion from European Committee for Medicinal Products for Human Use
- Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge® For Advanced Prostate Cancer
- ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
- Genasense® Can be Administered by Brief High-Dose IV Infusion
- NCCN Updates Central Nervous System Cancers Guidelines
- NCCN Updates Multiple Myeloma Guidelines
- NCCN Updates Non-Small Cell Lung Cancer Guidelines
- Phase I Results Announced for R1507 from Genmab’s Collaboration with Roche
- Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial
- ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar
- CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
- Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
- Flamel Technologies Announces Positive Top Line Results of a Clinical Trial of IFN-alpha-XL versus PegIntron™ in Patients with Chronic Hepatitis C Virus Infection
- Peptech successfully completes Phase I trial for PN0621
- Epicel™ Wins Marketing Approval for Severe Burn Victims
- Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan\'s Proprietary NanoCrystal® Technology
- Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
- Inovio Biomedical\'s DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
- Peptech successfully completes Phase I trial for PN0621
- MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
- TransMolecular Reports Positive Phase 1 Trial of 131Iodine Radiolabeled TM-601 in Glioma
- Alfacell\'s ONCONASE(R) Shows Promise as Radiation Sensitizer for Lung Cancer Treatment
- AlphaVax Announces Results from Phase 1 Influenza Vaccine Clinical Trial
- Encouraging Preliminary Data from TNFerade™ Phase II Rectal Cancer Study Presented at ASTRO Meeting
- PDUFA Date for Rilonacept (IL-1 Trap) Extended Three Months by FDA
- Cytori Receives European Approval for 2nd Generation Celution™ Stem & Regenerative Cell Processing System
- Excellent Results Received from GeoVax’s Full-Dose HIV/AIDS Vaccine Trial
- Human Genome Sciences Announces Full Presentation of Quality-of-Life Results from Phase 2b Trial of Albuferon® for Hepatitis C
- Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon® in Chronic Hepatitis C Patients who Failed to Respond to Previous Therapy
- IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
- IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
- New Data Presented on GARDASIL®, Merck\'s Cervical Cancer Vaccine, in Women Through Age 45
- Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
- Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma
- Affymax(R) Announces Hematide(TM) Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
- Positive Results From Peregrine Pharmaceuticals\' Bavituximab Phase l HCV Trial Presented at AASLD Meeting
- Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine
- Presentation of phase IIa results for Cytos Biotechnology\'s hypertension vaccine
- Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
- GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
- GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response
- FDA grants Kiadis Pharma lead product ATIR orphan drug designation
- Affymetrix GeneChip(R) Command Console(R) Software Simplifies Microarray Processing and Analysis Workflows
- Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccine
- Feature Bullet Nabi Biopharmaceuticals Announces Successful Completion of NicVAX® Phase 2b Trial
- Acrux developing nicotine spray to help smokers quit
- Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
- Data from STEP Study Presented at Open Scientific Session Confirm Merck\'s Investigational HIV Vaccine was not Effective
- Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA® (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
- BioGeneriX and Neose Technologies Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
- Dynavax Presents New Analysis of TOLAMBA(TM) Data: Analysis Points to Appropriate Patient Selection Criteria for Future Field Trial of TOLAMBA
- Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin\'s Lymphoma
- AKELA PHARMA ANNOUNCES FINAL POSITIVE RESULTS FROM ITS GROWTH HORMONE RELEASING HORMONE (GHRH) PHASE II TRIAL
- Crucell\'s Rabies Antibody Cocktail Granted Fast Track Status
- Genzyme Receives FDA Response Letter on Synvisc-One
- Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
- Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
- Athersys IND for MultiStem Authorized for Phase I Clinical Trial in Bone Marrow Transplant Support.
- Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
- Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
- # Abbott\'s HUMIRA® Receives Positive Opinion from EMEA for Treatment of Moderate to Severe Plaque Psoriasis
- TransMolecular Reports Positive Phase 2 Data from Study of Iodine Radiolabeled TM-601 in Recurrent Glioma
- Hana Biosciences Initiates Marqibo Phase 2 Clinical Trial in Metastatic Malignant Uveal Melanoma
- AVANT\'s Oral Combined Enterotoxigenic E. coli-Cholera Vaccine to Enter Phase 1 Safety Study Funded by the NIH
- Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
- Delcath Resumes Enrollment in Phase III and Phase II Trials
- Cardiome Initiates Phase 1 Study for GED-aPC
- ATL1102 Phase IIa Multiple Sclerosis Trial Update
- Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis
- Favourable results from GRAZAX® study in children
- Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis
- Introgen\'s ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
- MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatiod Arthritis
- Oralair® Grasses: Positive results of VO52.06 paediatric study
- Nventa Updates Progress With New HSPE7 In Phase 1 Trial In Cervical Dysplasia
- Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine
- Genmab Announces Update on Recruitment of Patients in Ofatumumab CLL Pivotal Study
- Oralair® Grasses: Positive results of VO52.06 paediatric study
- Bavarian Nordic A/S reports positive data from first EUA enabling study with IMVAMUNE® smallpox vaccine
- Adult Stem Cell Product to be Tested in Stroke Trial
- First Patient Completes StemCells, Inc.’s Phase I Clinical Trial
- Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
- Merck\'s ROTATEQ® Reduced Hospitalizations and Emergency Department Visits Due to G9P1A[8] Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data
- Arana Announces Phase II trials for Lead Compound ART621
- Amgen Announces Interim Results of Aranesp(R) \'\'PREPARE\'\' Study in Breast Cancer Patients
- ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
- Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine♦ (VNP40101M) in Combination with Stem Cell Transplantation
- THEREGEN COMPLETES ENROLLMENT OF ANGINERA PHASE I SAFETY TRIAL; PREPARES FOR PHASE II SUBMISSION
- Stem Cell Therapeutics Announces Receipt of No Objection Letter From Health Canada for Its Phase IIb Clinical Trial in Stroke
- CENTOCOR AND JANSSEN-CILAG SUBMIT APPLICATIONS REQUESTING APPROVAL OF USTEKINUMAB IN THE U.S. AND EUROPE FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
- Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
- Genentech Provides Update From Avastin FDA Advisory Meeting
- AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine
- Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin\'s Lymphoma
- Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
- Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
- ZymoGenetics Presents Positive Interim Phase 1 Results for IL-21 in Combination with Rituxan(R) in B Cell Lymphoma
- Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
- EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
- GENMAB’S HUMAX-CD38 ENTERS PHASE I/II CLINICAL TRIAL FOR MULTIPLE MYELOMA
- ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
- Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin\'s Lymphoma
- CELSION Re-submits Protocol for Special Protocol Assessment (SPA) for Pivotal Phase III Liver Cancer Trial
- ThromboGenics presents results of Phase I Trial of TB-402 at ASH
- GTC Obtains FDA Orphan Drug Designation for ATryn
- ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of Atacicept in Lupus Nephritis
- Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
- Phase II Study of IMC-1121B for Advanced Malignant Melanoma Commences Patient Enrollment
- Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
- December 12, 2007. GERON RECEIVES MILESTONE PAYMENT FROM MERCK TRIGGERED BY IND FILING FOR TELOMERASE CANCER VACCINE CANDIDATE
- Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases.
- Neurologix Gene Therapy Approach to Parkinson\'s Disease Granted Fast Track Designation From FDA
- Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
- MicroIslet Holds Positive Pre-IND Meeting for US Based Human Clinical Trial With FDA
- GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine
- Genzyme Announces FDA Approval of Thyrogen For Use In Thyroid Cancer Ablation
- ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma
- Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
- Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer
- DURECT Announces Positive ELADUR™ Phase IIa Study Results
- BioSphere Medical Receives CE Mark Approval for Transarterial Chemoembolization Using HepaSphere(TM) Microspheres
- Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
- Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
- Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination with Chemotherapy
- GlobeImmune Announces Initiation of Phase 2 Clinical Trial of GI-5005 in Patients with Chronic Hepatitis C
- Athersys Receives IND Authorization for MultiStem in Acute Myocardial Infarction
- Novavax Announces Favorable Interim Results From Human Clinical Trial For Its Pandemic Influenza Vaccine Program
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc
- GlaxoSmithKline files for FDA approval of Promacta/ Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder
- Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of MyVax(R) Personalized Immunotherapy
- R1507 Antibody to Enter Phase II Study to Treat Sarcoma
- Collegium Pharmaceutical Inc. Announces Final Study Results of its Successfully Completed Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
- DIAMYD FILES US IND FOR PHASE III TRIAL WITH DIABETES VACCINE
- Abbott\'s HUMIRA® Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
- FDA Receives New Data on Risks of Anemia Drugs
- GenVec Announces Protocol Changes for PACT Study After Discussions with FDA
- Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 Program
- Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax®-L at University of Pennsylvania
- VGX Pharmaceuticals announces successful completion of the first human study to assess the tolerability of CELLECTRA™ electroporator
- NEOPHARM Announces IND Filing for Novel Liposomal Delivery System of Docetaxel
- Acambis reports positive data from trials of universal influenza A vaccine
- Antigenics Reports Positive Data on QS-21 Stimulon® Adjuvant in Acambis’ Influenza A Vaccine
- HELSINN AND MGI PHARMA ANNOUNCE sNDA FOR ALOXI CAPSULES ACCEPTED FOR REVIEW BY U.S. FDA
- ZymoGenetics Begins Phase 2 Trial in Renal Cell Cancer Evaluating IL-21 Combined with Nexavar(R)
- Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma
- Sangamo BioSciences Initiates Phase 2 Clinical Trial of ZFP Therapeutic in Stem Cell Mobilization
- Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
- Baxter Announces Recombinant Factor IX Development Program for Hemophilia B
- Tacere Therapeutics Enters Collaboration and License Agreement with Pfizer to Develop and Commercialize RNAi Hepatitis C Drug
- Sangart, Inc. Initiates Dosing In Phase II Study Of Hemospan® In Chronic Critical Limb Ischemia
- Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
- Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
- Safety Monitoring Committee Recommends That Emergent BioSolutions Continue Its Hepatitis B Immunotherapy Phase II Trial
- Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
- TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody
- Transgene\'s therapeutic vaccine TG4010 shows promising preliminary phase IIb
- Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic
- BioCancell gets FDA approval for Phase IIb Bladder Cancer clinical trial
- ZymoGenetics Announces Special Protocol Assessment for Atacicept in General SLE
- FDA Extends Review Of GENASENSE® NDA Appeal in Chronic Lymphocytic Leukemia
- Interim Analysis Supports Continuation of Cell Genesys\' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
- NVENTA Completes Evaluation Of Second Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn\'s Disease
- Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
- Protox Initiates Phase 2 Prostate Cancer Study
- Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
- Celsion To Proceed With Phase II Pivotal Breast Cancer Trial After Receiving Supportive FDA Response
- ThromboGenics and BioInvent receive approval to begin clinical trials of TB-403 for the treatment of cancer
- FDA Approves ZymoGenetics\' RECOTHROM(TM) Thrombin, topical (Recombinant)
- StemCells, Inc. Provides Batten’s Clinical Trial Update
- MGI PHARMA Announces Results from Study Involving the Dual Implantation of Gliadel(R) Wafer and Radioactive Seeds for Treatment of Recurrent Glioblastoma Multiforme
- Abbott\'s HUMIRA® (adalimumab) Receives FDA Approval for Moderate to Severe Chronic Plaque Psoriasis
- DIAMYD ANNOUNCES COMPLETION OF TYPE 1 DIABETES VACCINE TRIAL
- Start of CytoFab Phase 2 Programme in Severe Sepsis
- Apthera Files a Phase III Special Protocol Assessment with FDA for NeuVax in Early-Stage Breast Cancer Patients
- Vyteris Announces First Successful Non-Invasive Delivery of Peptide Using Smart Patch Technology
- Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature
- Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
- Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
- Indevus Reports Additional Positive Phase III Trial Data for NEBIDO
- Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
- NVENTA Concludes Enrollment And Initial Dosing Of Third Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- ImmunoVaccine Technologies Discusses Phase I Clinical Trial Application
- Generex Biotechnology Receives Regulatory Approval to Initiate Phase III Clinical Trial for Generex Oral-lyn in First of the Global Locations Selected by the Company
- Celprogen Launches Caner Stem Cells
- Oramed Pharmaceuticals Commences Phase 1B Clinical Trials
- MolMed gets approval to start Phase III of TK in high risk acute leukaemia
- Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients With Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
- Start of OncoGel Phase 2b Study in Oesophageal Cancer
- Orthologic Announces FDA Acceptance of AZX100 IND Application in Dermal/Hypertrophic Scarring; Phase 1 Human Clinical Trial to Begin 1Q2008
- EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
- Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
- Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
- FDA Grants Priority Review for Schering-Plough\'s Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
- Alfacell Updates Status of ONCONASE Phase III Clinical Program
- Alchemia announces successful Pre-IND meeting with the US FDA
- Topigen Pharmaceuticals Initiates European Phase II Clinical Study of TPI ASM8 in Patients With Asthma
- MedImmune Submits Biologics License Application to FDA for Motavizumab
- Immunomedics Announces First Patient Dosing of Veltuzumab, Resulting in a Complete Response, in Immune Thrombocytopenic Purpura
- FDA Gives Green Light to Lpath\'s ASONEP IND Submittal
- Centocor Submits BLA for Ustekinumab to U.S. FDA
- Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP
- FDA Agrees to Review Cimzia File for the Treatment of Rheumatoid Arthritis
- OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
- Intercell’s therapeutic Hepatitis C vaccine meets primary endpoints in Phase II
- VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
- Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
- Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma
- Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
- Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data Demonstrating Alocrest to be Well-Tolerated With Promising Anti-Tumor Activity
- DIAMYD UPDATES FDA IND APPROVAL STATUS FOR PHASE III DIAMYD DIABETES STUDY IN THE US
- Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint
- YM BIOSCIENCES USA ENROLLS FIRST PATIENT IN PHASE II TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER
- Ophthotech Enrolls Its First Patient in a Phase I Anti-PDGF Macular Degeneration Trial
- MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
- Introgen\'s p53 Immunotherapy INGN 225 Begins Randomized, Controlled Clinical Trial in Patients with Small Cell Lung Cancer
- Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
- Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data Demonstrating Alocrest to be Well-Tolerated With Promising Anti-Tumor Activity
- Generex Biotechnology receives another regulatory approval to conduct Phase III clinical trial for Generex Oral-lyn™ for one of the largest global locations selected by the Company
- Alvine Pharmaceuticals Initiates Phase I Trial for ALV003
- DIAMYD RECEIVES FDA APPROVAL TO INITIATE CLINICAL STUDY IN CHRONIC PAIN
- Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
- Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
- Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Ophthotech
- Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
- GSK receives favourable recommendation by FDA advisory committee for Rotarix [rotavirus, live, oral]
- GSK\'s candidate adjuvanted pre-pandemic H5N1 vaccine reaches important EU regulatory milestone
- Wyeth\'s XYNTHA Approved by FDA for Treatment of Hemophilia A
- Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc
- Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
- Oxford BioMedica Announces Data Safety Monitoring Board Recommendation to Continue TroVax Phase III TRIST Study
- Harvest Technologies announces patient enrollment has begun for a clinical trial in India using autologous adult stem cells to treat patients with non-reconstructible Critical Limb Ischemia (CLI) due to Peripheral Arterial Occlusive Disease (PAOD)
- FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
- Artisan Pharma’s Lead Product, ART-123, Approved in Japan
- View Summary Prochymal(TM) Demonstrates Lasting Benefit in Heart Attack Patients; Osiris Receives FDA Clearance to Start Phase II Trial
- Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
- Bradmer Announces Phase II Results Published In Newly Diagnosed Glioblastoma Which Demonstrate Improved Survival And Support Upcoming Phase III Study
- Intercell completes Phase I clinical trial for improved seasonal Flu vaccine formulated with IC31
- Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema.
- Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study
- NVENTA Evaluation Complete For First Three Cohorts In HSPE7 Phase 1 Cervical Dysplasia Trial
- InvestBio Portfolio Company Presents Phase I/II Trial Results of Vaccine for Leukemia at American Society of Hematology Annual Meeting
- FDA grants Priority Review For Promacta / Revolade (Eltrombopag)
- Sequenom Releases Cancer EpiPanel for High-Throughput Methylation Profiling of Cancer-Associated Genes
- Biovitrum and Syntonix set to begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for the treatment of Hemophilia B
- FDA APPROVES ALOXI® (PALONOSETRON HCL) INJECTION
- Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
- Ichor Melanoma Vaccine Clinical Trial Moves to the Highest Dose Level
- Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
- BioMS Medical\'s Relapsing-Remiting
- Reports of increased survival in bird flu patients taking Tamiflu
- CTI Submits European Marketing Authorization Application for XYOTAX(TM)
- EU Commission Approves Updated Prescribing Information for Aranesp
- KaloBios Initiates Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma
- FDA Approval of Drug-Eluting Bead Clinical Trial
- Independent Data Safety Monitoring Board Recommends Continuation of Sangart’s Pivotal Phase III Trials of Hemospan Following Second Interim Review
- NVENTA Enrolls And Initiates Dosing Of Final Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- Genitope Corporation to Suspend Development of MyVax(R) Personalized Immunotherapy
- Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
- FDA Agrees to Amend Dendreon\'s Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
- Celsion Commences Global Phase III Study for Primary Liver Cancer
- RAVEN BIOTECHNOLOGIES ADVANCES RAV 18 THROUGH AGREEMENT WITH CMC ICOS BIOLOGICS
- Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
- Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis.
- DIAMYD GETS AUTHORIZATION TO BEGIN PHASE III STUDY IN THE US
- ALK-Abelló, the makers of GRAZAX®, Present Successful Phase III Clinical Study Results with Children
- Printer Friendly Version Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin\'s Lymphoma
- Oramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials of Oral Insulin Capsule
- Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
- Abiomed Receives Conditional FDA Approval for Impella 2.5 Study for Acute Myocardial Infarction (AMI) Patients
- Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical\'s Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
- Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
- Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
- Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome
- Phosphagenics today announced that it has received ethics approval to commence treating patients with Type 1 diabetes in a Phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/Insulin
- Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
- MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
- GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer at Memorial Sloan Kettering
- Supplemental Application for GARDASIL®, Merck\'s Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
- CHMP Upholds Negative Opinion for the EU Application for Cimzia in the Treatment of Crohn\'s Disease
- Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi) Therapeutic
- OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy
- Oxford BioMedica Report Encouraging New Phase II Trial Results with TroVax® in Prostate Cancer
- Nventa Announces Positive Interim Immunological Data From HSPE7 Phase 1 Cervical Dysplasia Trial
- THALLION PROVIDES UPDATE ON SHIGAMABS PROGRAM
- Neurologix Receives FDA Clearance to Initiate Phase 2 Trial in Parkinson\'s Disease Subjects
- Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
- OMRIX Biopharmaceuticals Initiates Phase II Clinical Trial for Fibrin Patch Product Candidate
- Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
- FAST Clinical Trial FDA Approved
- KaloBios Initiates Phase 1/2 Trial of Humaneered Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Cystic Fibrosis Patients
- Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
- Medarex Announces Ipilimumab Program Continues to Move Forward
- AVANT\'s Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
- FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age
- Crucell Announces First in Man Study with New Adenovirus Vector
- Oncophage® Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer
- Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
- ThromboGenics announces that it has completed patient enrolment for its Phase II MITI IV study
- Synthetic Blood International, Inc. Announces Plans to File Protocol for Phase II-b Oxycyte Clinical Trial
- Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
- Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment
- Pfizer Statement on Exubera Labeling Update in the United States
- Kamada was Granted New Orphan Drug Designation by the FDA, for its Aerosolized AAT for the treatment of Bronchiectasis
- CuraGen Advances CR011-vcMMAE into Phase II
- Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
- Genitope Corporation\'s MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial Results Available on Company Website
- Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
- Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
- Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in Korea
- U.S. Food and Drug Administration Approves ORENCIA® (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
- Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease
- Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
- New Phase III Data Confirm Phase II Findings of ADVEXIN(R) Efficacy
- ICLL\'s vaccine against JE: Excellent safety & immunogenicity in pediatric Phase II trials
- Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
- Significant Tumor-Specific Immune Response Observed in AVANT\'s Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme
- Celator Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
- Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
- MedImmune Advances Asthma Program With Start of a Phase 2 Trial in Europe and Australia and First U.S.-based Clinical Trial for Antibody Targeting IL-13
- Cell Genesys Reports Data on an Association Between Immune Response and Anti-Tumor Activity in Patients Receiving GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010)
- Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
- Actemra approved in Japan to treat patients with rheumatoid arthritis
- Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV
- Biovest Reports that Independent Data Monitoring Committee Recommends Unblinding of Phase 3 Clinical Results for its Anti-Cancer Vaccine, BiovaxID
- Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals
- ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial
- AlphaVax Announces Initial Analysis of Data from CMV Phase 1 Clinical Trial
- ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
- Abraxis BioScience Reports Promising Clinical Data in Advanced Pancreatic Cancer Using a Combination of nab-Paclitaxel (ABRAXANE(R)) and Gemcitabine (Gemzar(R))
- Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
- HUMAN GENOME SCIENCES COMPLETES ENROLLMENT IN FIRST OF TWO PHASE 3 LYMPHOSTAT-B TRIALS
- FDA agrees to first SPA for an oncolytic product
- Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn\'s Disease
- FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
- Nventa Completes Safety Evaluation On Final Cohort In HSPE7 Phase 1 Cervical Dysplasia Trial
- BIOLEX THERAPEUTICS RESEARCHERS PRESENT LOCTERON PHASE 2a HEPATITIS C TRIAL RESULTS AT EASL CONFERENCE
- Regeneron and Bayer HealthCare Have Announced Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration.
- MorphoSys Announces Completion of First Dosing in Phase 1 Trial for MOR103 Program
- Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
- KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate: KB003
- Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver
- Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
- Stem Cell Therapeutics Corp. Receives \"May Proceed\" From FDA for Its Phase IIb Clinical Stroke Trial and IND
- Orexo reports positive results from phase I study for OX19
- Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
- FDA Grants Market Clearance for the LipiScan™ Coronary Imaging System Developed By InfraReDx, Inc.
- Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis
- Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
- Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
- MERCK SERONO ANNOUNCES INITIATION OF PHASE II CLINICAL TRIAL OF ATACICEPT IN RELAPSING MULTIPLE SCLEROSIS
- PRO-PHARMACEUTICALS UPDATES NDA FILING FOR DAVANAT
- ZymoGenetics Presents Positive Results from RECOTHROM Thrombin, topical (Recombinant) Spray Study in Burn Patients
- Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
- Celgene Cellular Therapeutics Announces Clinical Transplant of Human Placenta-Derived Stem Cells
- Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra Clinical Trial in Neuroblastoma Patients
- QLT Completes Enrollment in the RADICAL Study
- MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
- Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
- Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
- Osiris Receives Approval for Use of Prochymal Under FDA Expanded Access Treatment Program
- FDA Grants Priority Review of Gamunex as a Treatment for Neurological Disorder CIDP
- PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study of Novel Systemic Antibiotic Compound
- Nventa Announces Additional Positive Immunological Data From HSPE7 Phase 1 Cervical Dysplasia Trial
- NOVELOS THERAPEUTICS ANNOUNCES POSITIVE RESULTS IN ONGOING PHASE 2 NEOADJUVANT BREAST CANCER TRIAL AT MUSC HOLLINGS CANCER CENTER
- Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
- Affymax and Takeda Announce Long-Term Hematide Safety and Effectiveness Data from Phase 2 Clinical Trials in Chronic Kidney Disease Patients with Anemia
- Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
- Endeavor II Four-Year Results Demonstrate Long-Term Safety and Durable Efficacy of Medtronic Drug-Eluting Stent
- Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin® Clinical Trial in Acute Spinal Cord Injury
- Active Biotech advances ANYARA into Phase III clinical trial
- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin
- Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
